West Pharmaceutical Services, Inc. (NYSE:WST) Shares Sold by Rafferty Asset Management LLC

Rafferty Asset Management LLC trimmed its position in West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 2.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,526 shares of the medical instruments supplier’s stock after selling 179 shares during the quarter. Rafferty Asset Management LLC’s holdings in West Pharmaceutical Services were worth $2,650,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of WST. Pathstone Family Office LLC raised its stake in West Pharmaceutical Services by 12.2% during the 3rd quarter. Pathstone Family Office LLC now owns 4,521 shares of the medical instruments supplier’s stock worth $1,696,000 after acquiring an additional 491 shares in the last quarter. Aptus Capital Advisors LLC acquired a new stake in West Pharmaceutical Services during the 3rd quarter worth $207,000. Canada Pension Plan Investment Board raised its stake in West Pharmaceutical Services by 73.9% during the 3rd quarter. Canada Pension Plan Investment Board now owns 148,709 shares of the medical instruments supplier’s stock worth $55,797,000 after acquiring an additional 63,200 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in West Pharmaceutical Services by 14.7% during the 3rd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,851 shares of the medical instruments supplier’s stock worth $5,572,000 after acquiring an additional 1,903 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ raised its stake in West Pharmaceutical Services by 166.3% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 37,159 shares of the medical instruments supplier’s stock worth $13,943,000 after acquiring an additional 23,207 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Stock Down 0.2 %

Shares of NYSE:WST opened at $314.68 on Friday. The company has a market cap of $22.92 billion, a price-to-earnings ratio of 41.51, a PEG ratio of 5.56 and a beta of 1.01. The firm’s 50-day simple moving average is $359.68 and its 200-day simple moving average is $362.56. The company has a quick ratio of 1.95, a current ratio of 2.61 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a fifty-two week low of $310.42 and a fifty-two week high of $415.73.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last issued its earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.27. The business had revenue of $695.40 million for the quarter, compared to the consensus estimate of $670.62 million. West Pharmaceutical Services had a net margin of 19.42% and a return on equity of 20.57%. The business’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.98 earnings per share. As a group, equities research analysts predict that West Pharmaceutical Services, Inc. will post 7.76 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 7th. Investors of record on Wednesday, July 31st will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.25%. The ex-dividend date of this dividend is Wednesday, July 31st. West Pharmaceutical Services’s dividend payout ratio is currently 10.55%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on WST. UBS Group lowered their price objective on shares of West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating on the stock in a research report on Friday, February 16th. StockNews.com downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Friday, February 16th. Finally, KeyCorp raised their price objective on shares of West Pharmaceutical Services from $440.00 to $470.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 13th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $435.20.

Read Our Latest Research Report on WST

Insider Buying and Selling

In related news, CEO Eric Mark Green sold 66,000 shares of the business’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the sale, the chief executive officer now owns 152,908 shares of the company’s stock, valued at $56,063,718.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of West Pharmaceutical Services stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the transaction, the chief executive officer now owns 152,908 shares in the company, valued at $56,063,718.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Chad Winters sold 815 shares of West Pharmaceutical Services stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $358.82, for a total transaction of $292,438.30. Following the transaction, the chief accounting officer now owns 1,309 shares of the company’s stock, valued at approximately $469,695.38. The disclosure for this sale can be found here. 0.53% of the stock is owned by insiders.

About West Pharmaceutical Services

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Featured Articles

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.